Supplementary Material for: Diverse Obesity Trajectories in a Family including Identical Twins with a Pathogenic MC4R Variant by figshare admin karger (2628495)

“…Twin 2 had a sedentary lifestyle and epilepsy and had a peak BMI of 30.1 kg/m2; she responded well to naltrexone-bupropion and BMI decreased to 26 kg/m2. …”

Antibodies information. by Xin Zhang (35492)

“…It has been reported that GsMTx-4, a specific blocker of the mechanosensitive ion channels Piezo1, can protect the integrity of the neuromuscular junction and promote nerve regeneration, and thus has the potential as a therapeutic agent for SCI. …”

IFN-γ and several PARP genes are upregulated in infected olfactory bulbs of JHMV infected mice. by Catherine M. Kerr (21492574)

Effects of the DCL on the number of categorized 50-kHz USVs induced by rhythmic stroking. by Rie Shimoju (20940045)

HFD changes lysosomal activity. by Tong Yue (6033305)

Mediation effect of muscle strength on the associations of obesity with incidence of knee OA. by Laijun Yan (19797455)

Expression levels of lysosome-related genes in HFD-fed flies and control group. by Tong Yue (6033305)

Image 1_Yacon root is a functional food beneficial for human health: a meta-analysis of clinical trials.pdf by Ling-Hui Pan (9341084)

“…The pooled results showed that YR significantly reduced BMI [SMD = −0.81, 95%CI (−1.54, −0.08)], decreased stool pH [SMD = −1.12, 95%CI (−1.61, −0.62)], softened stools [SMD = 0.94, 95%CI (0.08, 1.80)], facilitated defecation [SMD = 4.03, 95% CI (0.54, 7.52)], improved fiber consumption patterns [SMD = 0.58, 95%CI (0.18, −0.99)]. …”

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Normal odor or shock acuity in Rubicon RNAi or Atg1 overexpression flies. by Tong Yue (6033305)

Knockdown efficiency of lysosome-related genes in RNAi lines. by Tong Yue (6033305)

Transient suppression of <i>atg5</i> in neurons does not impair ITM. by Tong Yue (6033305)

Table 1_Bifidobacterium compound preparations as a supplementary treatment for severe ischemic stroke: a systematic review and meta-analysis.docx by Shenghua Lu (20762612)

“…Regarding immune function, the BCP combination group significantly increased IgA (MD = 0.50, 95% CI 0.36 to 0.63, p < 0.00001) and IgG (MD = 3.00, 95% CI 2.03 to 3.97, p < 0.00001). …”

Elevated autophagic levels in neurons restore HFD-induced memory impairment. by Tong Yue (6033305)

Table 1_Age-related lung structure changes by quantitative assessment: a cross-sectional study in a Chinese male cohort.docx by Meijuan Shi (16999551)

“…</p>Conclusion<p>Lung aging is not a linear process, and the lung structural alterations in the upper and lower lobes exhibit significant heterogeneity.…”

Clustering analysis of total and active RNAP II at genes during the transition from G1 to G2. by Douglas Maya-Miles (7024967)